258 related articles for article (PubMed ID: 15201644)
21. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
Abraira C; Henderson WG; Colwell JA; Nuttall FQ; Comstock JP; Emanuele NV; Levin SR; Sawin CT; Silbert CK
Diabetes Care; 1998 Apr; 21(4):574-9. PubMed ID: 9571345
[TBL] [Abstract][Full Text] [Related]
22. Beyond HbA1c.
Bloomgarden Z
J Diabetes; 2017 Dec; 9(12):1052-1053. PubMed ID: 28792665
[TBL] [Abstract][Full Text] [Related]
23. The impact of flash glucose monitoring on glycated hemoglobin in type 2 diabetes managed with basal insulin in Canada: A retrospective real-world chart review study.
Elliott T; Beca S; Beharry R; Tsoukas MA; Zarruk A; Abitbol A
Diab Vasc Dis Res; 2021; 18(4):14791641211021374. PubMed ID: 34275385
[TBL] [Abstract][Full Text] [Related]
24. Self-monitoring of blood glucose with finger tip versus alternative site sampling: effect on glycemic control in insulin-using patients with type 2 diabetes.
Knapp PE; Showers KM; Phipps JC; Speckman JL; Sternthal E; Freund KM; Ash AS; Apovian CM
Diabetes Technol Ther; 2009 Apr; 11(4):219-25. PubMed ID: 19344196
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
[TBL] [Abstract][Full Text] [Related]
26. HbA1c overtesting and overtreatment among US adults with controlled type 2 diabetes, 2001-13: observational population based study.
McCoy RG; Van Houten HK; Ross JS; Montori VM; Shah ND
BMJ; 2015 Dec; 351():h6138. PubMed ID: 26646052
[TBL] [Abstract][Full Text] [Related]
27. The Effect of Reduced Self-Monitored Blood Glucose Testing After Adoption of Continuous Glucose Monitoring on Hemoglobin A1c and Time in Range.
Puhr S; Calhoun P; Welsh JB; Walker TC
Diabetes Technol Ther; 2018 Aug; 20(8):557-560. PubMed ID: 30036082
[TBL] [Abstract][Full Text] [Related]
28. Reduction in HbA1c using professional flash glucose monitoring in insulin-treated type 2 diabetes patients managed in primary and secondary care settings: A pilot, multicentre, randomised controlled trial.
Ajjan RA; Jackson N; Thomson SA
Diab Vasc Dis Res; 2019 Jul; 16(4):385-395. PubMed ID: 31271312
[TBL] [Abstract][Full Text] [Related]
29. Sensor and software use for the glycaemic management of insulin-treated type 1 and type 2 diabetes patients.
Ajjan RA; Abougila K; Bellary S; Collier A; Franke B; Jude EB; Rayman G; Robinson A; Singh BM
Diab Vasc Dis Res; 2016 May; 13(3):211-9. PubMed ID: 27000105
[TBL] [Abstract][Full Text] [Related]
30. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis.
Yeh HC; Brown TT; Maruthur N; Ranasinghe P; Berger Z; Suh YD; Wilson LM; Haberl EB; Brick J; Bass EB; Golden SH
Ann Intern Med; 2012 Sep; 157(5):336-47. PubMed ID: 22777524
[TBL] [Abstract][Full Text] [Related]
31. Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide.
Roach ; Koledova E; Metcalfe S; Hultman C; Milicevic Z;
Clin Ther; 2001 Oct; 23(10):1732-44. PubMed ID: 11726007
[TBL] [Abstract][Full Text] [Related]
32. Structured self-monitoring of blood glucose regimens improve glycemic control in poorly controlled Chinese patients on insulin therapy: Results from COMPASS.
Ji L; Su Q; Feng B; Shan Z; Hu R; Xing X; Xue Y; Yang T; Hua Y
J Diabetes; 2017 May; 9(5):495-501. PubMed ID: 27249791
[TBL] [Abstract][Full Text] [Related]
33. Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group.
Saudek CD; Duckworth WC; Giobbie-Hurder A; Henderson WG; Henry RR; Kelley DE; Edelman SV; Zieve FJ; Adler RA; Anderson JW; Anderson RJ; Hamilton BP; Donner TW; Kirkman MS; Morgan NA
JAMA; 1996 Oct 23-30; 276(16):1322-7. PubMed ID: 8861991
[TBL] [Abstract][Full Text] [Related]
34. Characterization of cardiovascular outcomes in a type 2 diabetes glucose supply and insulin demand model.
Monte SV; Schentag JJ; Adelman MH; Paladino JA
J Diabetes Sci Technol; 2010 Mar; 4(2):382-90. PubMed ID: 20307400
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of glycemic variability in well-controlled type 2 diabetes mellitus.
Chon S; Lee YJ; Fraterrigo G; Pozzilli P; Choi MC; Kwon MK; Chin SO; Rhee SY; Oh S; Kim YS; Woo JT
Diabetes Technol Ther; 2013 Jun; 15(6):455-60. PubMed ID: 23617251
[TBL] [Abstract][Full Text] [Related]
36. Increased glycemic variability and decrease of the postprandial glucose contribution to HbA1c in obese subjects across the glycemic continuum from normal glycemia to first time diagnosed diabetes.
Fysekidis M; Cosson E; Banu I; Duteil R; Cyrille C; Valensi P
Metabolism; 2014 Dec; 63(12):1553-61. PubMed ID: 25308444
[TBL] [Abstract][Full Text] [Related]
37. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
Luo M; Kong X; Wang H; Zhai X; Cai T; Ding B; Hu Y; Jing T; Su X; Li H; Ma J
J Diabetes Res; 2020; 2020():6666403. PubMed ID: 33299890
[TBL] [Abstract][Full Text] [Related]
38. Correlation between 1,5-anhydroglucitol and glycemic excursions in type 2 diabetic patients.
Sun J; Dou JT; Wang XL; Yang GQ; Lü ZH; Zheng H; Ma FL; Lu JM; Mu YM
Chin Med J (Engl); 2011 Nov; 124(22):3641-5. PubMed ID: 22340217
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy.
Shimoda S; Iwashita S; Ichimori S; Matsuo Y; Goto R; Maeda T; Matsuo T; Sekigami T; Kawashima J; Kondo T; Matsumura T; Motoshima H; Furukawa N; Nishida K; Araki E
Endocr J; 2013; 60(10):1207-14. PubMed ID: 23912974
[TBL] [Abstract][Full Text] [Related]
40. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS
Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
